← Back to Clinical Trials
Recruiting Phase 1 NCT06920238

Use of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use

Trial Parameters

Condition Cannabis Use Disorder
Sponsor Trustees of Dartmouth College
Study Type INTERVENTIONAL
Phase Phase 1
Enrollment 15
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2025-04-13
Completion 2025-12
Interventions
Therabot-CALM

Brief Summary

The goal of this clinical trial is to learn if Therabot-CALM (Cannabis, Anxiety, Low Mood) has acceptability among users and could work to improve the symptoms of persons with cannabis use disorder and anxiety and/or depression. The main question it aims to answer is: What is the usability, feasibility, and acceptability of Therabot-CALM in persons with Cannabis Use Disorder and Anxiety and/or Depression? Participants will * Take a screening questionnaire * Participate in two virtual 1-hour interviews to provide feedback on app design and suggest features. * Engage with Therabot-CALM in a 4-week clinical trial and provide feedback on their app experience in a third virtual interview

Eligibility Criteria

Inclusion Criteria: * Is 18 years or older. * Meet criteria for current CUD (CUDIT-R\>=12) and MDD (PHQ-9\>=10), and/or GAD (GAD-7\>=10). * Have reliable access to the internet and a compatible device for Therabot-CALM. * Have willingness and capacity to provide informed consent and commit to participating in all assessments and interventions during the study. * Attend the first interview. Exclusion Criteria: * Moderate to High risk of STBs as determined by the C-SSRS or baseline questionnaires. * Current psychosis (as determined by brief psychosis screen). * Current participation in another digital mental health intervention.

Related Trials